Tivic Health Systems

Tivic Health Systems, Inc. operates as a bio-electronic health-tech company, which develops micro current therapy solutions for chronic diseases and conditions. The company was founded by Jennifer Ernst and John Claude on September 22, 2016 and is headquartered in Hayward, CA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Tivic Health Systems reports revenue growth and strategic advancements in Q1 2024

Tivic Health Systems showcased revenue growth and strategic initiatives in their Q1 2024 earnings call, emphasizing progress in bioelectronic medicine and clinical studies.
While facing challenges in managing a net loss and optimizing sales dynamics, the company's strengths lie in fiscal responsibility, product innovation, and market expansion.
Opportunities abound for Tivic Health to capitalize on their VNS program success, ClearUp product momentum, and strategic funding for future growth and value creation.
By balancing financial discipline with innovation, Tivic Health aims to navigate challenges, leverage strengths, and seize opportunities for sustainable growth and market leadership.

Tivic Health Systems advances VNS technology amidst financial challenges

Tivic Health Systems is making strides in VNS technology development and clinical research, despite facing financial and compliance challenges. With a strong patent portfolio and a focus on innovation, the company is well-positioned to capitalize on emerging opportunities in the medical device market.

Tivic Health Systems navigates challenges, eyes growth in VNS market

Tivic Health Systems faces financial challenges but shows resilience through strategic focus on profitability, innovation, and operational efficiency.
The company's progress in the VNS program and market assessment efforts position it well for future growth and market expansion opportunities.
With a new CFO onboard and a proactive approach to addressing product challenges, Tivic Health is poised to navigate challenges and capitalize on growth prospects.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tivic Health Systems, Inc. operates as a bio-electronic health-tech company, which develops micro current therapy solutions for chronic diseases and conditions. The company was founded by Jennifer Ernst and John Claude on September 22, 2016 and is headquartered in Fremont, CA.

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today issued the following letter from the CEO, Jennifer Ernst, providing additional information regarding the company's current report on Form 8-K filed with the SEC this afternoon. Dear Investors and Stakeholders in Tivic, As CEO of Tivic Health, I feel it is my duty to provide clarity to investors regarding the information include.

Letter from the CEO of Tivic Health, Jennifer Ernst.

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic”, “Company”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced the pricing of its previously announced public offering of 51,250,000 shares of its common stock at a public offering price of $0.04 per share. Gross proceeds from the offering are expected to be approximately $2.1 million before deducting placement agent fees and estimated offering expenses. Tivic intends.

Tivic Health Announces Pricing of $2.1 Million Public Offering of Common Stock

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that the Company has completed a full internal assessment of its supply chain and has established that its ClearUP product is Halal compliant. Of all the industries the American Halal Foundation (AHF) serves, there is probably none more critical than the pharmaceutical and supplement industry. From both a practical an.

Tivic Health Establishes Halal Compliance for ClearUP, FDA-Approved, Effective, Drug-Free Alternative for Sinus Pain, Pressure, and Congestion

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic”, “Company”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced the pricing of its previously announced public offering of 32,500,000 shares of its common stock at a public offering price of $0.055 per share. Gross proceeds from the offering are expected to be approximately $1.8 million before deducting placement agent fees and estimated offering expenses. Tivic intends.

Tivic Health Announces Pricing of $1.8 Million Public Offering of Common Stock

AC Immune

Opendoor

The allure of penny stocks is undeniable. Their low price and potential for massive returns create an inviting landscape for individuals, especially those with limited capital, to take a leap into the world of investing.

Trading Penny Stocks With Limited Capital: 3 Tops Tips

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic”, “Company”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that the Company has entered into a non-exclusive distribution agreement with Cardinal Health (RGH Enterprises) for Tivic's products. Cardinal Health is a leading distributor and manufacturer of medical products and services for healthcare facilities worldwide. With the goal of improving the lives of people.

Tivic Health Signs Distribution Agreement with Cardinal Health

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today that the company is expanding its target market for ClearUP to the vast population of consumers with allergy and congestion-related issues who are deprived of sleep, exercise, and concentration. A recent Tivic study with over 2,000 representative consumers conducted by Intellego Insights highlights patterns of the lar.

Tivic ClearUP Expands Target Market Offering to Include Individuals Who Are Sleep Deprived, Medication Restricted, and Athletes

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that its 2023 Annual Meeting of Stockholders (the “Annual Meeting”) scheduled for and convened on Tuesday, June 6, 2023, was partially adjourned to Wednesday, June 14, 2023, at 1:00 p.m. Pacific Standard Time. The record date for determining stockholders eligible to vote at the Annual Meeting will remain the cl.

Tivic to Reconvene Annual Meeting of Stockholders June 14, 2023

Tivic Health Systems (NASDAQ: TIVC ) stock is sliding lower on Tuesday after the company released its earnings report for the first quarter of 2023. That report starts with Tivic Health Systems revealing earnings per share of -11 cents in Q1.

Why Is Tivic Health Systems (TIVC) Stock Down 28% Today?

Tivic Health Systems, Inc. (TIVC) came out with a quarterly loss of $0.11 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.23 per share a year ago.

Tivic Health Systems, Inc. (TIVC) Reports Q1 Loss, Lags Revenue Estimates

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, is pleased to announce its financial results for the first quarter of 2023 ended March 31, 2023 (“Q1 2023”). First Quarter 2023 Financial Summary Gross profit increased 61.3% to $113 thousand in the first quarter of 2023, compared with $70 thousand in the first quarter of 2022, on a decrease of 12% in total revenue to $376 thousand i.

Tivic Reports First Quarter 2023 Financial Results

Faraday Future Intelligent Electric

Geron

Use these tips to analyze sectors to find penny stocks to buy The post Sector Analysis With Penny Stocks: 3 Top Tips  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Sector Analysis With Penny Stocks: 3 Top Tips

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report financial results for the first quarter 2023 via a pre-recorded conference call and webcast on Monday, May 15th, 2023 at 1:30 pm PT / 4:30 pm ET. Teleconference Details: Toll Free: 877-545-0523 International: 973-528-0016 Participant Access Code: 888610 Webcast Link https://www.webcaster4.co.

Tivic Health To Report First Quarter 2023 Financial Results on May 15th Via Conference Call and Webcast

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health Launches B2B Portal, Accelerates Healthcare Commercial Sales Expansion.

Tivic Health Launches B2B Portal, Accelerates Healthcare Commercial Sales Expansion

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced the appointment of veteran Kimberly Bambach to serve as Interim Chief Financial Officer of the company and the engagement of Christina Valauri as a strategic advisor to the Board of Directors. These additions aim to strengthen the company's financial foundation and bring growth and M&A expertise to the team.

Tivic Announces Appointment of New Interim CFO, Kimberly Bambach, and Strategic Advisor to the Board, Christina Valauri

Tivic Announces Appointment of New Interim CFO, Kimberly Bambach, and Strategic Advisor to the Board, Christine Valauri

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today that it has expanded its post-operative pain clinical study to include Otolaryngology and Facial Plastic Surgery patients. This study aims to investigate the potential benefits of a drug-free alternative to traditional post-operative pain management methods.

Tivic Health Expands Clinical Study of Post-Operative Pain in Nasal and Sinus Surgeries

SAN FRANCISCO & MANHASSET, N.Y.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic”) (Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced a research collaboration with The Feinstein Institutes for Medical Research to conduct a pilot clinical study that will test a novel non-invasive bioelectronic device approach for vagus nerve stimulation.

Tivic, The Feinstein Institutes for Medical Research Announce Pilot Study to Test Novel Non-Invasive Bioelectronic Approach to Vagus Nerve Stimulation

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced that it has filed its first patent in Vagus Nerve Stimulation with the U.S. Patent Office (USPTO), expanding its intellectual property portfolio into new clinical targets. Tivic's prior patents and current products have focused on the trigeminal and sympathetic nerve structures.

Tivic Expands Bioelectronic Portfolio; Files Patent Application for New Approach to Non-Invasive Vagus Nerve Stimulation

SAN FRANCISCO--(BUSINESS WIRE)---- $TIVC #healthcare--Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced its financial results for the year ending December 31, 2022.

Tivic Health Reports Fiscal Year 2022 Financial Results

SAN FRANCISCO--(BUSINESS WIRE)---- $TIVC #healthcare--Tivic Health® Systems, Inc. (“Tivic”) (Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced it has completed the supplier qualification and first article inspection of Microart Services, Inc., one of two new partners announced in Q4 of 2022.

Tivic Health Systems, Inc. Cuts Component Manufacturing Costs by 70%, Completes Second Key Supplier Qualification

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced that it will report financial results for the year ended December 31, 2022, via pre-recorded conference call and webcast on Friday, March 31, 2023, at 1:30 pm PT / 4:30 pm ET.

Tivic Health Systems, Inc. to Report Fiscal Year 2022 Financial Results on March 31st Via Conference Call and Webcast

SAN FRANCISCO--(BUSINESS WIRE)---- $TIVC #healthcare--Tivic Health® Systems, Inc. (“Tivic”) (Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced it has completed the supplier qualification and first article inspection of ALOM, one of two new partners announced in Q4 of 2022.

Tivic Cuts Final Assembly Production Costs by 40%, Completes First Key Supplier Qualification

SAN FRANCISCO--(BUSINESS WIRE)---- $TIVC #healthcare--Tivic Health® Systems, Inc. (“Tivic”) (Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced it has received recertification of ISO 13485, the international standard for medical device quality systems. The company also announced the recertification of ClearUP under the European Union Medical Device Certificate (CE-Mark).

Tivic Announces Successful Recertification of ISO 13485 Quality Management System and the European Medical Device CE-Mark

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic”) (Nasdaq: TIVC) (“Tivic” or the “Company), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced the closing of its previously announced underwritten public offering of an aggregate of 20,000,000 shares of common stock at a public offering price of $0.

News for Tivic Health Systems Stock (TIVC)